Brainpod March 2018: Considerations for the Use of DREADDs in Behavioral Neuroscience episode artwork

EPISODE · Mar 19, 2018 · 9 MIN

Brainpod March 2018: Considerations for the Use of DREADDs in Behavioral Neuroscience

from Springer Nature · host Springer Nature

There's a technology that's proven to be increasingly useful in the past decade — it's called DREADD, or "designer receptors exclusively activated by designer drugs." The current approach is to create a designer receptor that is unlocked by the drug, clozapine-n-oxide, or CNO. Researchers have used it to study the function of populations of neurons or of particular pathways in the brains in rodents, by using the DREADD technique to turn on and off these neurons or pathways. However, last year, a paper published in the journal Science called the use of DREADDs into question. Some people interpreted the paper as an overall indictment of the DREADD technology, though this wasn't the original intent of the authors. Listen to Neuropsychopharmacology's latest podcast to learn more! Article link: https://www.nature.com/articles/npp2017299

Episode metadata supplied by the publisher feed · Published Mar 19, 2018

Embed this episode

NOW PLAYING

Brainpod March 2018: Considerations for the Use of DREADDs in Behavioral Neuroscience

0:00 9:19

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Springer Nature?

This episode is 9 minutes long.

When was this Springer Nature episode published?

This episode was published on March 19, 2018.

Can I download this Springer Nature episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!